|
As the premier event in India’s pharmaceutical calendar, iPHEX 2025 stands apart as the largest platform to showcase the prowess of the Indian pharma industry to a global audience.
Further strengthening India’s position as the global leader in pharmaceuticals and healthcare, the Union Ministry of Commerce & Industry in collaboration with Pharmaceuticals Export Promotion Council of India (Pharmexcil) will be hosting the 11th edition of iPHEX 2025, concurrently with the debut of Bharat Health 2025. The mega event is scheduled to take place from September 4 to 6, 2025, at Bharat Mandapam, New Delhi.
This concurrent hosting marks a first-of-its-kind confluence that will bring together the entire healthcare and pharma spectrum under one umbrella — from formulations, APIs, biotech, and medical devices to Ayush, nutraceuticals, diagnostics, plant & machinery, and healthcare services.
According to K Raja Bhanu, Director General, Pharmexcil , the 11th Edition of IPHEX 2025 promises to be a pivotal event for the global pharmaceutical industry. It will bring together over 25,000 domestic visitors and 700 plus pharma exhibitors, with delegates from more than 111 countries.
“With BHARAT HEALTH 2025 and iPHEX 2025, we are shaping a transformative platform that aligns with India’s G20 and global health leadership vision” added Raja Bhanu.
“Bharat Health 2025 is a strategic platform to showcase India’s integrated healthcare capabilities to the world. The events are poised to attract thousands of domestic and global stakeholders, creating unparalleled networking, policy exchange, and trade facilitation opportunities. With iPHEX already having proven itself over 10 successful editions, the co-hosting with Bharat Health will elevate the experience and reach significantly,” Raja Bhanu had stated, while announcing the opening of online stall registrations.
Bharat Health 2025 is envisioned as a comprehensive platform that integrates all major healthcare segments with India’s globally recognized pharmaceutical strength, embodied by iPHEX. Together, they aim to position India not only as the “Pharmacy of the World”, but also as a trusted global health solutions provider.
Over 400 international business delegates and thousands of Indian trade visitors are expected to attend. The profile of overseas attendees includes pharmaceutical importers and distributors, government procurement agencies, regulatory officials, trade chambers and associations, manufacturers & R&D organizations
These delegates will represent more than 120 countries, spanning NAFTA, EU, Africa, CIS, ASEAN, South Asia, LAC, Oceania, and WANA regions.
Exhibitor categories to be showcased include formulations (branded & generic), Active Pharmaceutical Ingredients (APIs), vaccines, biotech & biosimilars, veterinary, nutraceuticals & Ayush, excipients & intermediates, medical devices & diagnostics, plant machinery & analytical equipment, services- (CRO, CDMO, clinical trials & healthcare, custom synthesis), regulatory & tech consultancy.
The event will feature a dedicated International Buyers Sellers Meet, a focused exhibition with over 700 stalls with a strong emphasis on research & development and innovation. It will also spotlight India’s leading pharmaceutical exporters—across formulations, biosimilars, bulk drugs, and surgical—who are serving healthcare needs in over 150 countries.
This year, the event expands its scope to include allied segments such as pharmaceutical machinery and Ayush products—broadening its relevance and impact.
IPHEX 2025 will feature Global Regulators Conclave, CEO Roundtable and RBSM fostering crucial discussions and collaborations to achieve these ambitious goals.
The event will include sector-specific sessions, and panel discussions on regulatory harmonization, global market expansion strategies, innovation in manufacturing, and the evolving landscape of pharma exports.
A dedicated exporters participation at the exhibition, Regulatory Conclave, and Global Buyer Forum will provide opportunities for knowledge-sharing, deal-making, and policy dialogue. Designed to align with India’s ambition of becoming a $65 billion pharma export powerhouse by 2030, summit embodies the spirit of “Powering Healthcare, Connecting Markets”—bringing together industry leaders, global stakeholders & policymakers to drive meaningful collaboration, unlock new trade corridors & elevate India’s role in global healthcare.
Since its inception in 2013, iPHEX has hosted over 5,000 foreign delegates, including regulators and buyers, and featured more than 4,000 Indian exhibitors across key cities like Mumbai, Hyderabad, New Delhi, and Ahmedabad.
As a cornerstone of the Brand India Pharma campaign, the exhibition strengthens India’s positioning as the “Pharmacy of the World” by enabling focused B2B meetings, regulatory dialogues, and strategic collaborations across global markets including NAFTA, EU, ASEAN, LAC, Africa, and GCC—driving expanded market access and global confidence in Indian pharmaceutical excellence.
The 2024 edition held at Greater Noida drew more than 20,000 visitors and 400 international delegates, setting the benchmark for this year’s edition.
Pharmexcil initiatives to explore new markets
With India’s top five countries for pharma exports being USA, UK, Brazil, South Africa, and France, the Pharmexcil has taken several path breaking initiatives in helping member companies to explore new markets amidst changing geopolitical situation and US Tariff policies to boost pharma trade and retain the tag of “Pharmacy to the World”.
Key functions and activities of Pharmexcil include assisting Indian pharmaceutical companies in accessing and expanding into international markets through various initiatives, such as trade fairs, exhibitions, and business delegations, providing information and guidance on international regulatory requirements and standards to ensure compliance and facilitate exports, informing and assisting members in availing benefits from government schemes and policies related to the pharmaceutical sector.
Dedicated WhatsApp helpdesk for members
To enhance communication and provide efficient support to its members, the Pharmexcil has introduced dedicated WhatsApp numbers as the primary point of contact for various member services. This initiative aims to streamline interactions and ensure timely assistance for issues, queries, suggestions, and feedback related to key matters.
The new WhatsApp chat service will enable real-time communication, providing a convenient platform for discussing pending issues, seeking clarifications, or sharing suggestions. However, it is important to note that these numbers are designated for chat communication only, and no calls will be accepted. The service is available on working days during office hours from 10 am to 6:30 pm.
Talks with US on strengthening trade
Pharmexcil has opened a focussed dialogue with the US on strengthening trade facilitation, regulatory alignment, and market access for Indian pharmaceutical products, as part of the meeting held at the Embassy of India (EOI), USA.
Raja Bhanu had discussions with Dr. Ajay Kumar, Minister (Commerce) EOI, USA to address key issues related to pharmaceutical exports.
Pharmexcil also had discussions with Akhilesh Singh, Counsellor, Commerce, Indian Embassy, USA and discussed matter pertaining to tariffs and impact on the pharmaceutical industry. This was focused on strengthening trade frameworks, addressing regulatory challenges and enhancing India’s global pharmaceutical presence.
Media delegation from Eastern and Southern Africa
Africa’s growing pharmaceutical needs and its rising stature as a strategic export destination for Indian generics took centre stage during a high-level familiarization visit hosted by the Pharmexcil.
The 28-member media delegation from Eastern and Southern Africa, visiting under the aegis of the ministry of external affairs (MEA), received a deep dive into India’s pharma capabilities and its expanding footprint across the African continent.
The session held recently at Pharmexcil’s regional office in Mumbai, was led by Rollins John, director, and Sumantha Chaudhary, adviser to Pharmexcil. The visit aimed to foster a better understanding of India’s pharmaceutical export ecosystem and promote sustained engagement with African media stakeholders.
Study on Norway’s pharma procurement landscape
In a strategic move to bolster Indian pharmaceutical exports to the Nordic region, the Indian Embassy in Oslo, with the support of the ministry of commerce and industry, Government of India, under the Market Expansion Activity (MEA), has successfully commissioned a detailed study on the pharmaceutical and vaccine procurement landscape in Norway. The findings are expected to guide Indian pharmaceutical exporters in navigating one of Europe’s most regulated and quality-sensitive markets.
The report, released by the Pharmexcil, sheds light on the nuances of Norway’s healthcare procurement system, emphasizing regulatory alignment, early engagement, and market adaptability.
Recognition of IP in Fiji
In a significant stride towards strengthening Indian pharma footprint in the Pacific region, the Indian Pharmacopoeia Commission (IPC) has signed a Memorandum of Understanding (MoU) with the Ministry of Health & Medical Services (MoHMS), Republic of Fiji.
This strategic partnership paves the way for the recognition of the Indian Pharmacopoeia (IP) as a standard for evaluating Market Authorization (MA) applications for Indian-manufactured medicinal products intended for the Fijian market.
Rising exports to Brazil
India’s rising exports to Brazil signal trust in its pharmaceutical capabilities, while imports from Brazil into India demonstrate the balanced and mutually beneficial nature of this trade partnership, informed pharma trade experts.
Major collaborations between Brazil and India were also a part of the ongoing discussions with Kenneth Felix Haczynski da Nóbrega, Ambassador of Brazil to India particularly in the areas of contract manufacturing organizations (CMOs) and the co-development of innovative molecules.
Ambassador of Brazil to India emphasized the strengthening of Brazil-India relations, particularly in sectors such as healthcare and pharmaceuticals. The Ambassador has consistently highlighted the deepening bilateral ties between the two nations, focusing on shared values, mutual trust, and collaborative efforts in various domains.
Talks to fast-track Myanmar pharma products
In a major development to boost pharma trade between Myanmar and India,
Raja Bhanu and Dr Win Kyaing, chairman of the Myanmar Chamber of Commerce for Pharmaceutical and Medical Device (MCCPMD) have started discussing
the possibilities of trade cooperation to fast-track approval for pharma products in Myanmar.
Myanmar is one of India’s important destinations of pharmaceutical exports and about 60 per cent of medicinal requirements of Myanmar are being contributed by India.
“A significant development also includes Dr. Win Kyaing, chairman MCCPMD consent to sign a MoU at iPHEX 2025 expanding global pharmaceutical cooperation,” informed Raja Bhanu.
|